Further studies are required in order to propose better strategies for overcoming resistance to PARP inhibitor therapy in ovarian cancers.
BRCA1/2 mutated ovarian cancer after a complete or partial response (CR/PR) to platinum-based chemotherapy; niraparib is approved as maintenance treatment in platinum-sensitive, relapsed, ovarian cancer after a CR/PR to platinum-based chemotherapy; rucaparib is approved as third-line treatment in BRCA1/2 mutated, platinum sensitive, relapsed high-grade ovarian cancer. In the United States, olaparib is approved as fourth-line treatment in BRCA1/2 mutated, advanced ovarian cancer and first-line maintenance treatment in BRCA-mutated, advanced ovarian cancer after a CR/PR to first-line platinum-based chemotherapy; rucaparib is approved as third-line treatment in BRCA1/2 mutated, advanced ovarian cancer; niraparib is approved as maintenance treatment in platinum-sensitive, recurrent ovarian cancer after a CR/PR to platinum-based chemotherapy. There are some minor differences between the indications of these drugs in Europe and USA, based on different clinical trials. [7] [8] [9] [10] All three PARP inhibitors approved for ovarian cancer treatment have substantial PFS advantages over placebo in the maintenance setting. 11, 12 Clinical trials of these three PARP inhibitors are ongoing, and these drugs are expected to have substantial PFS advantages over placebo in the treatment setting as well.
BRCA1/2 mutations remain the strongest genetic indicators of sensitivity to PARP inhibitors. 13 However, 40 − 70% of BRCA1/2-mutated ovarian cancers fail to respond to PARP inhibitors. [14] [15] [16] [17] In addition, the remarkable efficacy of PARP inhibitors in ovarian cancer is not restricted to patients with germline BRCA1/2 mutations but extends to those with tumours with HR repair pathway deficiencies. 18 Tumours with mutations in certain genes that are not directly involved in DNA repair but are related to the HR pathway or influence the effect of HR pathway genes are sensitive to PARP inhibitors. 19 This review discusses preclinical and clinical data that describe methods of predicting the response to PARP inhibitors, the potential mechanisms of resistance to PARP inhibitors, and measures to circumvent resistance to PARP inhibitors.
| BIOMARKERS PREDICTING CLINICAL BENEFIT FROM PARP INHIBITORS

| High correlation between platinum sensitivity and PARP inhibitor response
"BRCAness" is used to describe the phenotype shared between non-BRCA1/2-mutated ovarian cancers and BRCA1/2-mutated ovarian cancers. 20 The molecular characteristics of "BRCAness" might lie in the aberration of certain genes involved in the HR repair pathway, such as BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK1, CHEK2, FAM175A, MRE11A, NBN, PALB2, RAD51C and RAD51D. 21 Ovarian cancers with a "BRCAness" phenotype exhibit high sensitivity to both platinum and PARP inhibitors, and the overall survival rate is higher in these cancers than in ovarian cancers without a "BRCAness" phenotype. 21, 22 Hence, platinum sensitivity might indicate the molecular characteristics of BRCAness and be a potential phenotypic marker for PARP inhibitor sensitivity.
The PARP inhibitor response is closely related to platinum sensitivity in clinical trials of PARP inhibitors. Arms in clinical trials of PARP inhibitors were balanced for platinum sensitivity, prior chemotherapeutic regimen and prior lines of chemotherapy. 23 Olaparib is the earliest and most extensively investigated PARP inhibitor, and the relationship between the olaparib response and platinum sensitivity has been deeply evaluated. A significant association between the olaparib clinical benefit rate and platinum sensitivity in BRCA1/2-mutated ovarian cancers was confirmed; the clinical benefit rate of olaparib therapy was 69.2% in platinum-sensitive, 45 .8% in platinum-resistant and 23.1% in platinum-refractory BRCA1/2-mutated ovarian cancers. 16 The response to olaparib is best in germline BRCA1/2-mutated, platinum-sensitive ovarian cancers and worst in BRCA1/2 wild-type, platinum-resistant ovarian cancers. 14, 15, 24, 25 Thus, platinum sensitivity may be a good predictor of the PARP inhibitor response in BRCA1/2 wild-type ovarian cancers;
indeed, in a phase II trial of olaparib, half of the platinum-sensitive ovarian cancers with wild-type BRCA1/2 responded to olaparib, but only 4% of the platinum-resistant ovarian cancers with wild-type BRCA1/2 responded. However, platinum resistance might not be sufficiently powerful to rule out clinical benefit from PARP inhibitors in BRCA-mutated cancers, since 60% of platinum-sensitive, BRCA1/2-mutated ovarian cancers and 33% of platinum-resistant, BRCA1/2-mutated ovarian cancers in the same trial responded to olaparib. 15 Notably, a response to platinum does not guarantee a response to PARP inhibitors. Unlike PARP inhibitor sensitivity, platinum sensitivity may result from defective nucleotide excision repair (NER).
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The platinum-induced interstrand and intrastrand cross-links (ICLs) between purine bases in DNA are extremely deleterious and are more cytotoxic than the SSBs caused by PARP inhibitors. [27] [28] [29] [30] In addition, the partial restoration of HR by genetic alterations such as 53BP1 loss in BRCA1-mutated tumour cells (discussed below) is insufficient to repair the complex cross-links caused by platinum agents; tumours with partially restored HR repair retain sensitivity to platinum but exhibit resistance to PARP inhibitors. 29, 31, 32 Olaparibresistant, heavily pretreated BRCA1/2-mutated ovarian cancers have been observed to retain the potential to respond to subsequent chemotherapy, even platinum-based agents. In addition, an increased platinum-to-platinum interval during olaparib treatment indicated a response to subsequent platinum agents. 33 However, an increased number of previous platinum-based therapies may indicate the development of secondary mutations that restored the functions of the BRCA1/2 or RAD51C/D genes and influenced the sensitivity to PARP inhibitors. 
| Potentially relevant gene aberrations and combination strategies for PARP inhibitor sensitization
To identify which gene aberrations might induce synthetic lethality with PARP inhibitors, researchers studied the five major DNA damage repair pathways operational in cells. 3, 34 The combination of NER deficiency and PARP inhibition has been demonstrated not to be synthetically lethal. 26 However, although NER deficiency does not lead to synthetic lethality, the combination of PARP inhibition and deficiencies in other DNA repair pathways such as BER, HR, non-homologous end joining (NHEJ) and even mismatch repair (MMR) has been demonstrated to be synthetically lethal. 35 Since the HR pathway is a high-fidelity repair pathway for accurately repairing DSBs and involves the BRCA1/2 proteins, researchers have focused on the HR pathway.
Approximately 50% of high-grade serous ovarian cancers (HGSOCs) are deficient in HR because of germline or somatic mutations in BRCA1/2 (20%), the epigenetic silencing of BRCA1 (11%), the amplification or mutation of EMSY (8%), the deletion of PTEN (7%), the hypermethylation of RAD51C (3%), mutations in ATM or ATR (2%) or mutations in Fanconi anemia genes (5%). 36 The key genes and modulators of the HR pathway that might induce synthetic lethality with PARP inhibitors are under investigation. Figure 1 shows the aberrations in HR genes or potentially relevant HR genes and Figure 2 presents the molecular process of DNA damage repair associated with PARP inhibitor sensitivity and resistance. The DNA recombinase RAD51 is a crucial downstream protein in the HR repair pathway. 44 RAD51 is relocalized within the nucleus in response to DNA damage to form distinct foci, which are thought to represent assemblies of proteins at these sites of HR repair. PARP inhibition leads to the failure of SSB repair via the BER pathway, and persistent SSBs result in stalled replication forks and subsequently develop into DSBs. In HR-proficient cells, these DSBs can be repaired by error-free HR accompanied by an increase in RAD51 foci formation, whereas in HR-deficient cells, repair by error-prone NHEJ results in genomic instability, chromosomal aberrations, cell cycle arrest and ultimately cell death. 45 Hence, RAD51 nuclear foci can be a surrogate biomarker for HR repair functionality and can be detected by a functional RAD51 immunofluorescence assay. The absence of RAD51 foci formation represents a functional deficiency of HR repair. 46 The RAD51 foci formation assay successfully predicted the in vitro response to PARP inhibitors in primary cultures from the ascitic fluid of ovarian cancer patients. 22, 45 Using RAD51
foci as a biomarker, PARP inhibitor cytotoxicity was observed in 93% of HR-deficient tumours but in no HR-proficient tumours. 45 Furthermore, irradiation-induced RAD51 foci formation assay accurately predicted which patient-derived xenograft (PDX) models were sensitive to PARP inhibition in vitro and in vivo. 47 However, in a study by AlHilli et al, the decreased formation of RAD51 foci failed to predict a response to PARP inhibitors in HGSOC PDX models. 19 Five RAD51 paralogs exist: RAD51B, RAD51C, RAD51D, XRCC2
and XRCC3. Germline mutations in both RAD51C and RAD51D
were identified in families with ovarian cancer. Loss-of-function mutations in RAD51D predispose individuals to ovarian cancer but not to breast cancer. 44 Germline RAD51D mutations were found in 0.8% of subjects with ovarian cancer not selected for a family history of ovarian cancer. 48 When treated with RNA interference targeting RAD51D, tumour cells exhibit a sensitivity to olaparib similar to that achieved by the silencing of BRCA2. 44 RAD51C acts sequentially with RAD51 at the DNA damage site to repair DNA damage, and RAD51C depletion leads to impaired RAD51 foci formation, resulting in impaired DNA repair. RAD51C promoter methylation has been studied thoroughly. RAD51C was found to be densely methy- The PARP-ATR inhibitor combination caused the complete regression of BRCA-mutated ovarian cancer PDX tumours, while the PARP-CHK1 inhibitor combination led only to tumour suppression rather than to tumour regression. Nevertheless, compared with the PARP inhibitor alone, both of the combinations showed significantly improved efficacy. 54 The phase II trial combining an ATR inhibitor (AZD6738) with a PARP inhibitor (olaparib) to treat recurrent ovarian cancers is ongoing (CAPRI: NCT 03462342).
ATM and CHK2 are also important cell cycle checkpoint proteins. 55 ATM phosphorylates CHK2 and promotes CHK2 activation. FANCD2 ) levels, and decreased RAD51 foci formation, thus disrupting HR repair and predicting sensitivity to PARP inhibitors. 68 A genome-wide synthetic lethality screen for candidate PARP inhibitor sensitivity genes identified CDK12 deficiency as a clinically relevant biomarker for PARP inhibitor sensitivity. 69 The phase I study of an
The molecular process of DNA damage repair associated with PARP inhibitor sensitivity and resistance. 1) During the repair of DSBs by NHEJ, damage is recognized and bound by Ku70-Ku80 heterodimers, DNA-PKcs and Artemis are activated, and XRCC4 and DNA ligase-IV are recruited to complete DNA end joining. NHEJ occurs throughout the cell cycle and directly ligates the ends of a DSB. The loss of the abovementioned crucial proteins in the NHEJ pathway might induce resistance to PARP inhibitors. 2) During the repair of DSBs by HR, DNA lesions are recognized by the MRE11-NBS1-RAD50 (MRN) complex, and DNA end resection is initiated. In a PALB2-dependent fashion, BRCA2 is recruited, which loads RAD51 onto the DNA to mediate strand invasion on the homologous sister chromatid. HR occurs mainly in the S and G2 phases. The switch between HR and NHEJ depends on the activity of S phase CDKs, which phosphorylate CtIP in order to activate the MRN complex and stimulate DNA end resection, which is regulated by 53BP1, REV7 and RIF1. The abovementioned crucial proteins in the HR pathway might thus affect PARP inhibitor sensitivity. 3) In addition, the cell cycle checkpoint pathway and the FA-BRCA1 pathway are involved in HR, and crucial proteins in these pathways are associated with PARP inhibitor sensitivity 27, 46 JIANG ET AL. 
| Genomic scar analysis of "BRCA-like" tumours
The gain or loss of large chromosomal regions or even whole chromosomes is termed genomic scarring and can be observed as copy number variations resulting from the failure of DNA damage repair. 76 Genomic scar analysis is based on DNA repair pathways rather than on DNA repair genes. Since the mutational analysis of all the genes associated with HR pathways is increasingly complex, 46 genomic scar analysis is believed to be more efficient in identifying "BRCA-like" tumours and has thus been developed to discriminate between HRproficient and HR-deficient tumours. 46, 77, 78 and 10% of BRCA wild-type, low-LOH tumours responded to rucaparib. The phase III ARIEL3 trial, in which the LOH cut-off was elevated to 16%, assessed the ability of tumour genomic LOH to predict the response to rucaparib in the maintenance setting following platinum-based chemotherapy. The tumour genomic LOH test was not sufficiently precise to deselect patients who would not benefit from rucaparib; more than 30% of patients with BRCA wild-type, low-LOH tumours in the rucaparib group achieved clinical benefit from rucaparib for more than 1 year, but less than 5% in the placebo group experienced this benefit. These results demonstrated that these tests can be used to identify patients with BRCA wild-type, platinum-sensitive ovarian cancers who might benefit from PARP inhibitors. However, a negative result on these tests is not sufficiently precise to exclude a clinical benefit from PARP inhibitors among BRCA wild-type ovarian cancers in either the treatment or maintenance setting. 11, 12, 85 However, more clinical trials are warranted to further investigate the role of these HRD biomarkers in predicting benefits from PARP inhibitors. . 92 The inhibition of DNA-PK induced both the resistance to rucaparib and the recovery of HR function in a BRCA1-defective cell line. 92 The loss of Artemis, another critical factor in NHEJ, was found to be associated with resistance to niraparib in an HGSOC PDX model. 19 Thus, the synthetic lethality between PARP inhibition and HR deficiency requires the concomitant competence of the NHEJ pathway. The increased expression of the ATP-dependent efflux pump ABCB1 (MDR1), which encodes the membrane drug efflux transporter P-glycoprotein, might readily export PARP inhibitors from tumour cells and lead to resistance to the PARP inhibitors olaparib or rucaparib but not to veliparib or AZD2461, both of which are poor P-glycoprotein substrates. 29, 99, 100 However, this resistance can be reverted using the ABCB1 inhibitors verapamil, elacridar and tariquidar. PARP inhibitors in ovarian cancer cell lines in vitro. 103 The PARP1 expression level is positively correlated with PARP inhibitor sensitivity. 104 For example, an acquired low expression level of PARP1 is a potential cause of resistance to PARP inhibitors in PDX models. 103 Furthermore, cells with PARP1 mutations were 100-fold more resistant to PARP inhibitors than were cells with wild-type PARP1. 105 Mutations both within and outside the PARP1 DNA-binding domains alter PARP1 trapping and induce PARP inhibitor resistance. 106 Cancer cells may up-regulate the HR repair pathway to compensate for the loss of BER as a result of PARP1 inhibition, and the HR and BER pathways interact to regulate cancer cell viability via decreased PARP1 and increased RAD51 expression levels. This mechanism may explain the concomitant RAD51 foci formation and PARP inhibitor resistance in both PDX models and patient-derived samples harbouring germline BRCA mutations. 107 In addition, this resistance was observed to be reverted upon combination treatment with an ATM inhibitor in PDX models. 
| MECHANISMS UNDERLYING PARP INHIBITOR RESISTANCE
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